New Funding Boosts French Leukemia Research, Offering Hope for Improved Treatments
Toulouse, France – A significant investment of nearly 2 million euros has been awarded to an hematology team at the Oncopole in Toulouse, France, to spearhead a large-scale national study aimed at improving the treatment of acute myeloid leukemia (AML). This funding, secured at the end of February 2026, will support the “Massive-2” clinical trial, a follow-up to the successful “BIG-1” study conducted between 2015 and 2025. The initiative promises to advance care for a cancer that disproportionately affects younger adults, offering a renewed sense of optimism for patients and their families.
Acute myeloid leukemia, a cancer of the blood and bone marrow, impacts approximately 3,000 individuals in France each year, typically those between the ages of 18 and 60. Although current treatments, including intensive chemotherapy and sometimes bone marrow transplantation, can achieve remission in about half of patients, therapeutic advancements have lagged behind those seen in other blood cancers in recent years. This new research seeks to address that gap and improve long-term survival rates.
Building on Past Success: The BIG-1 and BIG-2 Trials
The team at the Oncopole, led by Professor Christian Recher of the University Hospital of Toulouse (CHU de Toulouse), is uniquely positioned to lead this crucial research. Their prior work with the BIG-1 trial was instrumental in standardizing treatment practices across France, ensuring that all patients receive a consistent level of expertise and access to innovative therapies. Professor Recher explained that BIG-1 demonstrated the benefits of reducing chemotherapy doses without compromising treatment effectiveness, a finding that challenged conventional wisdom in hematology.
BIG-2, slated to begin later in 2026, will involve 1,300 patients nationwide, a substantial number given the incidence of AML. The study will focus on incorporating new molecules into existing treatment regimens to enhance both progression-free survival and overall survival. A key component of the research will also be improving the detection of relapse, a critical challenge in AML management.
Leveraging New Technologies for Early Relapse Detection
One of the most promising aspects of the BIG-2 trial is its emphasis on utilizing advanced technologies to identify minimal residual disease (MRD) – the presence of a small number of cancer cells remaining after initial treatment. Professor Recher highlighted that conventional methods can only detect one cancer cell in 200, whereas techniques like flow cytometry and molecular biology can identify as few as one cell in 10,000 or even 100,000. This increased sensitivity allows for earlier intervention and potentially prevents relapse.
“If we can better detect residual cancer cells that are invisible to the naked eye, we can improve relapse prevention,” Professor Recher stated. “For patients with detectable residual disease, we will intensify treatment. For others, regular monitoring will allow us to detect relapse before it becomes clinically visible, enabling earlier intervention.” This proactive approach represents a significant shift in AML management, moving towards personalized treatment strategies based on individual risk profiles.
The Role of the IUCT Oncopole in Cancer Research
The Oncopole in Toulouse is a leading comprehensive cancer center dedicated to research, diagnosis, and treatment. The Institut Universitaire du Cancer de Toulouse (IUCT) Oncopole plays a central role in coordinating clinical trials and fostering collaboration between researchers and clinicians. Recent breakthroughs at the Oncopole include the identification of a new therapeutic combination – azacitidine and ivosidenib – as the standard of care for AML patients with a specific IDH-1 gene mutation. This combination, detailed in the New England Journal of Medicine, has been shown to triple survival rates for this patient subgroup.
This success underscores the importance of targeted therapies in AML treatment. Ivosidenib is an inhibitor of mutant IDH1 enzymes, and its combination with azacitidine has proven more effective and better tolerated than previous treatment options. The IUCT Oncopole’s involvement in international studies, like the AGILE trial, demonstrates its commitment to advancing cancer care on a global scale.
Funding Details and Future Outlook
The 1,991,000 euro funding for the BIG-2 trial comes from the French Directorate-General for Care Supply (Direction Générale de l’Offre de Soins) as part of the “Hospital Clinical Research Program in Oncology – PHRC-K 2025” call for projects from the National Cancer Institute (INCa). This financial support will be crucial in enabling the research team to conduct a rigorous and comprehensive study that has the potential to significantly improve outcomes for AML patients across France.
The ongoing research at the Oncopole, coupled with the promising results of the BIG-2 trial, offers a beacon of hope for individuals battling acute myeloid leukemia. By leveraging cutting-edge technologies and fostering collaboration, French researchers are at the forefront of the fight against this challenging cancer. The next major milestone will be the commencement of patient enrollment in the BIG-2 trial later in 2026, with initial results anticipated in the coming years.
Key Takeaways:
- A 2 million euro investment will fund a national study (BIG-2) to improve AML treatment in France.
- The study, led by Professor Christian Recher at the Oncopole in Toulouse, will involve 1,300 patients.
- Advanced technologies will be used to detect minimal residual disease and prevent relapse.
- A new therapeutic combination (azacitidine and ivosidenib) has emerged as the standard of care for certain AML subtypes.
This research represents a significant step forward in the fight against acute myeloid leukemia. Stay informed about the progress of the BIG-2 trial and other advancements in cancer research by visiting the IUCT Oncopole website and following updates from the National Cancer Institute (INCa). Share this article with your network to raise awareness about this important work.
Worth a look